联合检测LDHA 和PD-L1 在晚期胃癌PD-1 抑制剂疗效预测及预后评估中的价值
左学良， 陈志强， 董润雨， 王智雄， 蔡娟 - 中国癌症杂志, 2023 - china-oncology.com
… (LDHA) and programmed death ligand-1 (PD-L1) expressions in … that PD-L1 combined
positive score (CPS)<5 and LDHA high … the invasion of pituitary adenoma by secreting CCL17[J]. …
positive score (CPS)<5 and LDHA high … the invasion of pituitary adenoma by secreting CCL17[J]. …
[HTML][HTML] 垂体腺瘤免疫治疗现状及进展
田智杰， 张越林 - Advances in Clinical Medicine, 2021 - hanspub.org
… therapeutic strategies for pituitary adenomas. However, … )和程序性细胞死亡1 (programmed
cell death ligand, 1),可以通过… ,但PD-1/PD-L1阻滞剂受到了更多的关注,因为PD-L1在肿瘤细胞中…
cell death ligand, 1),可以通过… ,但PD-1/PD-L1阻滞剂受到了更多的关注,因为PD-L1在肿瘤细胞中…
免疫检查点抑制剂相关内分泌不良反应的研究进展
陈莉群， 徐明智 - 中国肿瘤临床, 2020 - cjco.cn
… (programmed death-ligand 1,PDL1)以及细胞毒性T淋巴细胞… With the increasing use of ICIs,
more immune-related adverse … -1或PD-L1的抗体通过与PD-1或PD-L1相结合,从而阻断PD-1与…
more immune-related adverse … -1或PD-L1的抗体通过与PD-1或PD-L1相结合,从而阻断PD-1与…
[HTML][HTML] 免疫检查点抑制剂相关糖尿病2 例报道及文献回顾
任尧尧， 张琳琳， 王瑜， 钟殿胜 - Chinese Journal of Lung Cancer, 2022 - ncbi.nlm.nih.gov
… ，1例在使用程序性死亡受体-配体1（programmed cell death-Ligand 1, PD-L1）单抗7个月后出现
血糖增高，1例在使用PD-1单… Two patients were both elderly women, case 1 had increased …
血糖增高，1例在使用PD-1单… Two patients were both elderly women, case 1 had increased …
垂体腺瘤免疫微环境及免疫治疗的研究进展
郭晓鹏， 幸兵， 马文斌 - 基础医学与临床, 2022 - journal11.magtechjournal.com
… 体配体1(programmed death ligand 1, PD⁃L1),C⁃X⁃ C趋化因子受体4(C⁃X⁃…
Increased expression of programmed death ligand1 (PD⁃L1) in hu⁃ man pituitary tumors [ J…
Increased expression of programmed death ligand1 (PD⁃L1) in hu⁃ man pituitary tumors [ J…
[HTML][HTML] 程序性死亡蛋白-1 抑制剂治疗晚期肺癌出现垂体免疫不良反应3 例
顾阳春， 刘颖， 谢超， 曹宝山 - Journal of Peking University (Health …, 2022 - ncbi.nlm.nih.gov
… ligand 1, PD-L1)的抑制剂广泛用于肺癌治疗, 但引起的免疫相关不良反应(… Case 1 was a
68-year-old male diagnosed with metastatic lung adenocarcinoma with high expression of PD-L1. …
68-year-old male diagnosed with metastatic lung adenocarcinoma with high expression of PD-L1. …
侵袭性垂体瘤治疗方法的研究进展
刘红艳， 谷伟军， 母义明 - 解放军医学院学报, 2023 - xuebao.301hospital.com.cn
… -line chemotherapy drug for aggressive pituitary tumors, but it is … 体-1(programmed death
receptor-1,PD-1) 抑制剂,程序性死亡受体… ligand, PDL1) 抑制剂和细胞毒性T 淋巴细胞相关抗原4 (…
receptor-1,PD-1) 抑制剂,程序性死亡受体… ligand, PDL1) 抑制剂和细胞毒性T 淋巴细胞相关抗原4 (…
难治性泌乳素瘤药物治疗进展
牙森， 吴永刚 - 中国肿瘤临床, 2020 - cjco.cn
… Abstract: Prolactinomas are the most common functional pituitary adenomas. Most patients
… of the tumor difficult; these characteristics are coupled with a high postoperative recurrence …
… of the tumor difficult; these characteristics are coupled with a high postoperative recurrence …
作用于垂体治疗库欣病的药物研究进展
李玲， 张会娟 - 中国全科医学, 2022 - chinagp.net
… resection of the pituitary adenoma. Medication therapy is the … of actions,aiming to increase
medical workers' understanding of … 5.2 PD-1/PD-L1 阻断剂的应用现已证明PD-1/PD-L1 阻断 剂…
medical workers' understanding of … 5.2 PD-1/PD-L1 阻断剂的应用现已证明PD-1/PD-L1 阻断 剂…
免疫检查点抑制剂相关垂体免疫不良反应的诊治.
顾阳春， 谢超， 曹宝山 - Chinese Journal of Oncology …, 2022 - search.ebscohost.com
… Since June 2018, when the first programmed cell death 1 (PD⁃1) inhibitor, nivolumab, was
… in coping with irAEs from PD⁃1 and PD⁃1 ligand 1 (PD⁃L1) blockade therapies. In October …
… in coping with irAEs from PD⁃1 and PD⁃1 ligand 1 (PD⁃L1) blockade therapies. In October …